Garvan's mission is to make significant contributions to medical research that will change the directions of science and medicine and have major impacts on human health.
The Garvan Institute of Medical Research is one of the world’s leading biomedical research institutes, seeking to understand human biology and the common diseases affecting our community, including cancer, neurological disorders, autoimmunity and other malfunctions of the immune system, diabetes, obesity and metabolic disease, and osteoporosis and other disorders of bone.
Our approach is to use the most advanced genomic, imaging, and cellular technologies, model systems and analytical methods to better understand, reduce the incidence, and improve treatments for these diseases; to establish innovative enterprises; and to transform health policy and healthcare.
STRATEGIC OBJECTIVES AND ACTIONS
OBJECTIVE 1: TRANSFORMATIVE SCIENCE
Establish Garvan as a leader in the integration of biological, genomic and clinical data to make transformative advances in knowledge and its application to human health.
1.1 Recruit and nurture gifted (a) early- and mid-career researchers, (b) high quality students, and (c) highly skilled professional support staff
1.2 Maintain and enhance Garvan’s capability in (a) genomics, (b) epigenomics and (c) cellular genomics
1.3 Further develop and integrate access to state-of-the-art capabilities in (a) genome editing, (b) cell biology and functional genomics, (c) imaging (d) metabolomics, proteomics and microbiomics, and (e) biodata visualisation
1.4 Develop computational and bioinformatic skills and promote big data-enabled research to understand the biological drivers of health and disease
OBJECTIVE 2: SUSTAINABILITY
Ensure Garvan has the financial resources and human capital to develop and sustain a visionary agenda into the future.
2.1 Increase Garvan’s untied reserves through major donor and bequest campaigns
2.2 Increase research income from (a) philanthropy, (b) industry and commercial activities
2.3 Optimise the intersection of Garvan’s research and development priorities with those of the NHMRC, the MRFF and other research funding agencies
2.4 Actively enhance our engagement and collaborations with (a) UNSW, (b) hospitals and (c) other national and international institutions that are aligned with Garvan’s vision to leveragefunding from multiple sources and enhance
OBJECTIVE 3: HEALTH IMPACT
3.1 Recruit clinician scientists through joint appointments with St Vincent’s and other hospitals
3.2 Work with St Vincent’s Hospital and precinct partners in the development of collaborations and implementation of precision medicine
3.3 Engage with government and other agencies to inform policies, programs and investments in precision medicine and health
OBJECTIVE 4: INNOVATION
4.1 Attract entrepreneurs, investors and business leaders to engage with Garvan and mentor researchers in entrepreneurship and innovation
4.2 Establish an ecosystem for identifying and developing products and services with commercial potential
4.3 Incentivise and support entrepreneurial researchers and students and equip them for careers that span business, industry and academia